Found: 4
Select item for more details and to access through your institution.
Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations.
- Published in:
- Cancer Research & Treatment, 2024, v. 56, n. 3, p. 847, doi. 10.4143/crt.2023.1197
- By:
- Publication type:
- Article
FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 9, p. 10597, doi. 10.1002/cam4.5798
- By:
- Publication type:
- Article
Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S350, doi. 10.1016/j.clml.2017.07.176
- By:
- Publication type:
- Article
Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder.
- Published in:
- Therapeutic Advances in Urology, 2014, v. 6, n. 5, p. 181, doi. 10.1177/1756287214541798
- By:
- Publication type:
- Article